Clinical trial
Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities
NCT06859008 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 25, 2025
- Completion date
- January 31, 2029
- Enrollment
- 37 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia/small lymphocytic lymphoma, recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma, recurrent diffuse large b-cell lymphoma, recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent mantle cell lymphoma, recurrent nodal marginal zone lymphoma, recurrent splenic marginal zone lymphoma, refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, refractory diffuse large b-cell lymphoma, refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory mantle cell lymphoma, refractory nodal marginal zone lymphoma, refractory splenic marginal zone lymphoma